Effect of N-Acetylcysteine on Neutrophil Lymphocyte Ratio And Length of Stay In COVID-19 Patients

Universitas Sebelas Maret120 enrolled

Overview

This research is a study that compares the administration of N-acetylcysteine at various doses with the outcomes of COVID-19 patients, namely the neutrophil-to-lymphocyte ratio and length of stay.

This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into four groups. The control group K0 received standard therapy without NAC, while the treatment group K1 received NAC injections of 1200mg/day, K2 NAC tablets 3x400mg/day, and K3 NAC tablets 3x200mg/day. Different tests using Way ANOVA and LSD or Kruskal-Wallis and Mann-Whitney.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

120

Conditions

COVID-19

Interventions

N-acetyl cysteineDRUG

N-acetyl cysteine dosage 600 mg and 1200 mg

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * moderate or severe grade confirmed COVID-19 (patients with symptoms and radiological examination showing pneumonia with or without signs of severe pneumonia: SpO2\<90%, respiratory rate\>30x/min, and severe respiratory distress) who were admitted to UNS Hospital and age 18-60 years old Exclusion Criteria: * patients who died during the treatment period

Locations (1)

Universitas Sebelas Maret Hospital

Sukoharjo, Central Java, Indonesia

Outcomes

Primary Outcomes

Neutrophil to lymphocyte ratio

Time frame: Change of Neutrophil to lymphocyte ratio at 7 day

Length of stay

Time frame: From date of randomization until the date of return from hospital

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.